Tuesday, August 16, 2011

Generic Drug Makers May Soon Pay for Overseas Plant Inspections - ABC News

Media_httpaabcnewscom_ieima

One infamous result of such oversight problems occurred in 2008, when Chinese manufacturers substituted a fake ingredient for the main one in a supply of the blood thinner heparin. The contaminated drug killed 81 people in the United States and sickened hundreds of others. The FDA never inspected the plants that manufactured the main ingredient.

Ovarian, Breast Cancer Drug Shortage Watch Video

Drug Prices: Why Will They Drop? Watch Video

Why Pay More For Blood Pressure Drugs? Watch Video

Hoping to prevent similar situations from happening again, Mylan Pharmaceuticals is helping to negotiate an agreement between the FDA and generic drug makers that would provide $299 million a year for inspections. That sum would come from fees paid by the manufacturers themselves.

Posted via email from Jack's posterous

No comments: